1. ALLA AKTIER
  2. NYHETER
  3. NANOLOGICA

Nanologica

Nyheter Nanologica Nyheter alla bolag

NANOLOGICA AB CHANGES DATES FOR INTERIM REPORT

MARKN.

Nanologica’s interim report for the first quarter will be published on April 16 instead of April 17.

The report will be published on the company’s website at approx. 08.10.

For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Thanks to their efficient and long-lasting purification, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of an increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective medicines through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Attachments
NANOLOGICA AB CHANGES DATES FOR INTERIM REPORT

Datum 2025-04-15, kl 17:35
Källa MFN
Bifogade filer
NANOLOGICA AB CHANGES DATES FOR INTERIM REPORT
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.